Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT03334253

Low-Dose Atropine for Treatment of Myopia

Conditions: Myopia

Sex: All
Ages: 5 Years – 12 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 200
Sponsor: Jaeb Center for Health Research

Location: University of Alabama at Birmingham Birmingham Alabama

Summary

Study Objectives The objectives for this randomized trial are: 1. To determine the efficacy of daily low-dose atropine (0.01%) for slowing myopia progression over a two-year treatment period in children aged 5 to less than 13 years (Primary Outcome On-Treatment). 2. To determine the efficacy of atropine treatment on myopia progression 6 months following cessation of low-dose atropine treatment (Secondary Outcome Off-Treatment). Synopsis of Study Design The current study is designed as an efficacy study, making effort to maximize adherence to treatment group assignments. After a run-in phase during which all participants are treated with daily artificial tear eyedrops for 2-4 weeks (and glasses are updated if required) to assess their ability to adhere to daily eye drops, participants are randomly assigned to daily atropine or placebo for 24 months, followed by 6 months off treatment.

Eligibility Criteria

Inclusion Criteria: * Age 5 years to \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT03334253). StuddyBuddy aggregates publicly available trial information.